Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

17.50CHF
4:30pm GMT
Change (% chg)

CHF-0.24 (-1.35%)
Prev Close
CHF17.74
Open
CHF17.56
Day's High
CHF17.75
Day's Low
CHF17.27
Volume
214,652
Avg. Vol
296,523
52-wk High
CHF28.46
52-wk Low
CHF15.20

Chart for

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF2,096.57
Shares Outstanding(Mil.): 119.12
Dividend: --
Yield (%): --

Financials

  IDIA.S Industry Sector
P/E (TTM): -- 69.32 32.54
EPS (TTM): -- -- --
ROI: -- 8.89 13.82
ROE: -- 10.00 15.25

UPDATE 2-Swiss Idorsia says 'stay tuned' for deals as it manages pipeline

* CFO says J&J was fully aware of Actelion DOJ probe (Adds details about possible deals, comments from CEO, CFO, details about Actelion settlement)

07 Feb 2019

BRIEF-Idorsia: First Patient Recruited Into React - Phase 3 Registration Study With Clazosentan

* ANNOUNCES FIRST PATIENT RECRUITED INTO REACT - PHASE 3 REGISTRATION STUDY WITH CLAZOSENTAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

05 Feb 2019

BRIEF-Idorsia Starts Multiple-Dose Efficacy And Safety Study With Cenerimod For Treatment Of Systemic Lupus Erythematosus

* IDORSIA INITIATES A MULTIPLE-DOSE EFFICACY AND SAFETY STUDY WITH CENERIMOD FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

07 Jan 2019

BRIEF-Idorsia's Selatogrel Phase 2 Clinical Studies Meet Their Objective

* IDORSIA'S P2Y12 RECEPTOR ANTAGONIST - SELATOGREL - PHASE 2 CLINICAL STUDIES MEET THEIR OBJECTIVE

18 Dec 2018

BRIEF-Idorsia Maintains Collaboration Agreement With Reveragen

* FOLLOWING RECEIPT OF CLINICAL STUDY REPORT FOR PHASE 2A STUDY WITH VAMOROLONE, WILL PAY REVERAGEN USD 15 MILLION TO MAINTAIN AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

05 Nov 2018

BRIEF-Idorsia Says Representative Of Former Axovan Shareholders Filed Complaint Against Actelion

* SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS CLAIMS DEMERGER OF ACTELION AND IDORSIA WOULD TRIGGER ACCELERATION OF ALL OUTSTANDING MILESTONE PAYMENTS FOR CLAZOSENTAN

24 Oct 2018

BRIEF-Idorsia 9Mth US GAAP Net Loss Of CHF 278 Mln

* US GAAP OPERATING RESULTS IN 9M 2018: LOSS OF CHF 271 MILLION

23 Oct 2018

Earnings vs. Estimates